Introduction: The 2021 European Society of Cardiology (ESC) Guidelines recommend the use of four different classes of drugs for heart failure with reduced ejection fraction (HFrEF): beta blockers (BB), sodium-glucose cotransporter-2 inhibitors (SGLT2i), angiotensin receptor/neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRAs). Moreover, the 2023 ESC updated Guidelines suggest an intensive strategy of initiation and rapid up-titration of evidence-based treatment before discharge, based on trials not using the four-pillars. We hypothesized that an early concomitantly administration and up-titration of four-pillars, compared with a conventional stepwise approach, may impact the vulnerable phase after hospitalization owing to HF. Methods: This prospective, single center, observational study included consecutive in-hospital patients with HFrEF. After performing propensity score matching, they were divided according to treatment strategy into group 1 (G1), with predischarge start of all four-pillars, with their up-titration within 1 month, and group 2 (G2) with the pre Guidelines update stepwise four-pillars introduction. HF hospitalization, cardiovascular (CV) death, and the composite of both were evaluated between the two groups at 6-month follow-up. Results: The study included a total of 278 patients who completed 6-month follow-up (139 for both groups). There were no differences in terms of baseline features between the two groups. At survival analysis, HF hospitalization risk was significantly lower in G1 compared with G2 (p < 0.001), while no significant differences were observed regarding CV death (p = 0.642) or the composite of CV death and HF hospitalization (p = 0.135). Conclusions: In our real-world population, patients with HF treated with a predischarge and simultaneous use of four-pillars showed a reduced risk of HF hospitalization during the vulnerable phase after discharge, compared with a conventional stepwise approach.

Strategy for an early simultaneous introduction of four-pillars of heart failure therapy. results from a single center experience / Severino, Paolo; D'Amato, Andrea; Prosperi, Silvia; Mariani, MARCO VALERIO; Myftari, Vincenzo; LABBRO FRANCIA, Aurora; Cestiè, Claudia; Tomarelli, Elisa; Manzi, Giovanna; Birtolo, Lucia Ilaria; Marek-Iannucci, Stefanie; Maestrini, Viviana; Mancone, Massimo; Badagliacca, Roberto; Fedele, Francesco; Vizza, Carmine Dario. - In: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. - ISSN 1175-3277. - 24:5(2024), pp. 663-671. [10.1007/s40256-024-00660-6]

Strategy for an early simultaneous introduction of four-pillars of heart failure therapy. results from a single center experience

Paolo Severino
Co-primo
;
Andrea D'Amato
Co-primo
;
Silvia Prosperi
Secondo
;
Marco Valerio Mariani;Vincenzo Myftari;Aurora Labbro Francia;Claudia Cestiè;Elisa Tomarelli;Giovanna Manzi;Lucia Ilaria Birtolo;Viviana Maestrini;Massimo Mancone;Roberto Badagliacca;Francesco Fedele
Penultimo
;
Carmine Dario Vizza
Ultimo
2024

Abstract

Introduction: The 2021 European Society of Cardiology (ESC) Guidelines recommend the use of four different classes of drugs for heart failure with reduced ejection fraction (HFrEF): beta blockers (BB), sodium-glucose cotransporter-2 inhibitors (SGLT2i), angiotensin receptor/neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRAs). Moreover, the 2023 ESC updated Guidelines suggest an intensive strategy of initiation and rapid up-titration of evidence-based treatment before discharge, based on trials not using the four-pillars. We hypothesized that an early concomitantly administration and up-titration of four-pillars, compared with a conventional stepwise approach, may impact the vulnerable phase after hospitalization owing to HF. Methods: This prospective, single center, observational study included consecutive in-hospital patients with HFrEF. After performing propensity score matching, they were divided according to treatment strategy into group 1 (G1), with predischarge start of all four-pillars, with their up-titration within 1 month, and group 2 (G2) with the pre Guidelines update stepwise four-pillars introduction. HF hospitalization, cardiovascular (CV) death, and the composite of both were evaluated between the two groups at 6-month follow-up. Results: The study included a total of 278 patients who completed 6-month follow-up (139 for both groups). There were no differences in terms of baseline features between the two groups. At survival analysis, HF hospitalization risk was significantly lower in G1 compared with G2 (p < 0.001), while no significant differences were observed regarding CV death (p = 0.642) or the composite of CV death and HF hospitalization (p = 0.135). Conclusions: In our real-world population, patients with HF treated with a predischarge and simultaneous use of four-pillars showed a reduced risk of HF hospitalization during the vulnerable phase after discharge, compared with a conventional stepwise approach.
2024
heart failure with reduced ejection fraction (HFrEF); beta blockers (BB); sodium-glucose cotransporter-2 inhibitors (SGLT2i); angiotensin receptor/neprilysin inhibitor (ARNI) and mineralocorticoid receptor antagonists (MRAs)
01 Pubblicazione su rivista::01a Articolo in rivista
Strategy for an early simultaneous introduction of four-pillars of heart failure therapy. results from a single center experience / Severino, Paolo; D'Amato, Andrea; Prosperi, Silvia; Mariani, MARCO VALERIO; Myftari, Vincenzo; LABBRO FRANCIA, Aurora; Cestiè, Claudia; Tomarelli, Elisa; Manzi, Giovanna; Birtolo, Lucia Ilaria; Marek-Iannucci, Stefanie; Maestrini, Viviana; Mancone, Massimo; Badagliacca, Roberto; Fedele, Francesco; Vizza, Carmine Dario. - In: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. - ISSN 1175-3277. - 24:5(2024), pp. 663-671. [10.1007/s40256-024-00660-6]
File allegati a questo prodotto
File Dimensione Formato  
Severino_Strategy_2024.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 797.9 kB
Formato Adobe PDF
797.9 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1713366
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact